Iterum Therapeutics reports mixed topline results from Phase 3 sulopenem trial

Iterum Therapeutics Logo

Iterum Therapeutics (NASDAQ:ITRM) reported mixed topline results from its clinical trial assessing sulopenem, an anti-infective compound, in combination with probenecid for the treatment of uncomplicated urinary tract infections (uUTIs). 

The trial enrolled 1,670 women who were randomized to receive either oral sulopenem and probenecid – a medication that increases uric acid excretion – twice daily for five days, or oral ciprofloxacin twice daily for three days.

Sulopenem achieved its primary endpoint by demonstrating superiority to ciprofloxacin in patients with baseline quinolone-resistant pathogens. Sulopenem did not achieve its primary endpoint of non-inferiority to ciprofloxacin in patients with organisms susceptible to quinolones, due to the rate of asymptomatic bacteriuria post-treatment.

Based on past discussions with the FDA, Iterum believes that achievement of either primary endpoint is expected to provide a path to marketing approval. 

“Approximately five-to-six million urinary tract infections in the U.S. every year are caused by quinolone resistant pathogens,” Iterum’s CEO, Corey Fishman, said in a statement.

“If approved, sulopenem would provide a treatment option for women with infections due to these resistant pathogens. Sulopenem is the first new oral antibiotic to demonstrate success in treating uUTIs in a Phase 3 trial in over twenty years. We anticipate a pre-NDA meeting with the FDA in the third quarter of 2020 to discuss a path forward,” he added. 

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.